Related Experiment Videos
Indications for immediate angiotensin-converting enzyme inhibition in patients with acute myocardial infarction
T H LeJemtel1, J S Hochman, E H Sonnenblick
1Division of Cardiology, Albert Einstein College of Medicine, Bronx, New York 10461, USA.
Insights
Early angiotensin-converting enzyme (ACE) inhibition after myocardial infarction improves survival and reduces heart failure. ACE inhibitors are well-tolerated and recommended for patients with left ventricular dysfunction or heart failure post-myocardial infarction.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Myocardial infarction (MI) can lead to left ventricular dysfunction and heart failure.
- Early intervention is crucial for improving outcomes after MI.
Purpose of the Study:
- To evaluate the benefits of early angiotensin-converting enzyme (ACE) inhibition in patients post-myocardial infarction.
- To assess the impact of ACE inhibition on survival, morbidity, and heart failure development.
Main Methods:
- Initiation of ACE inhibition within days of myocardial infarction.
- Assessment of patients with asymptomatic left ventricular systolic dysfunction and symptomatic heart failure.
Main Results:
- ACE inhibition demonstrated beneficial effects on survival and morbidity.
- It prevented heart failure in patients with asymptomatic left ventricular dysfunction.
- Improved hemodynamic and clinical variables in patients with existing heart failure.
Conclusions:
- Early ACE inhibition is indicated for acute myocardial infarction patients with left ventricular dysfunction or heart failure.
- ACE inhibition may also benefit patients with failed thrombolytic therapy post-MI.
Abstract:
When initiated a few days after myocardial infarction, angiotensin-converting enzyme inhibition exerts beneficial effects on survival and morbidity in patients with asymptomatic left ventricular systolic dysfunction or symptomatic heart failure. During the acute phase of a myocardial infarction, angiotensin-converting enzyme inhibition appears to be well tolerated, to prevent the development of heart failure in patients with asymptomatic left ventricular systolic dysfunction and to improve the hemodynamic and clinical variables of heart failure when present. Accordingly, early angiotensin-converting enzyme inhibition is clearly indicated in patients with acute myocardial infarction associated with asymptomatic left ventricular dysfunction or clinical evidence of heart failure. Angiotensin-converting enzyme inhibition may also be beneficial when thrombolytic agents fail to restore coronary patency in patients with acute myocardial infarction.